genome

Aegera Therapeutics Collaboration with Human Genome Sciences Leads to the Initiation of a Phase 1 Clinical Trial with Lead IAP Inhibitor HGS1029 and Receipt of First Milestone Payment ... diabetic neuropathy and is in Phase I clinical studies. Website: CONTACT: Donald Olds, MSc, MBA, Chief...